Digbi Health to Present Study on the Gut Microbiome's Role in Enhancing Endogenous GLP-1 Production at the 2024 Obesity Society Conference
The study demonstrates how altering the gut microbiome can increase the body's natural GLP-1 production — reducing medication dosage, improving adherence and lowering costs.
MOUNTAIN VIEW, Calif., October 3, 2024 /Digbi Newswire/ -- Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the Obesity Society Conference. The study demonstrates how the Digbi Health program successfully alters the gut microbiome to produce compounds that increase the body's natural production of endogenous GLP-1 (glucagon-like peptide-1).
This approach shows promise in reducing GLP-1 medication dosages, improving weight loss, improving drug adherence, and lowering treatment costs for employers, health plans and consumers, while enhancing long-term weight loss outcomes.
As GLP-1 drugs such as Ozempic™, Wegovy™ and Zepbound™ become more widely prescribed for obesity, Digbi Health's research addresses common challenges associated with these medications.
Why employers and health plans are paying attention
Digbi's approach resonates with employers and health plans seeking new ways to eliminate fragmented point solutions and reduce healthcare costs, particularly GLP-1-related drug costs.
The company's competitive edge lies in its dataset and bioinformatics platform, which consolidates millions of data points across genetics, gut microbiome progression, metabolic health and disease markers. That data allows Digbi to personalize care, identify patentable bio-signatures, generate health risk profiles, and stratify patient care for optimized treatment.
Originally distributed via Business Wire.
About Digbi Health
Digbi Health is the precision biology care company unifying metabolic and inflammatory care — including obesity, cardiometabolic, gastrointestinal, and inflammatory disorders. These illnesses share a root cause: a mismatch between an individual's biology and the one-size-fits-all lifestyle guidance they've been given. Digbi combines the gut microbiome, genetics, advanced blood biomarkers, and continuous digital health data to build a unique biological profile for each individual and identify what is driving their disease. AI then personalizes lifestyle treatment and, when needed, clinical treatment, delivered through the first precision-biology AI-orchestrated national telehealth platform. Through Digbi Labs, we invest in our vision of making chronic illness optional and advancing healthspan — partnering with leading universities, pharmaceutical companies, and scientific and clinical laboratories, running distributed human trials and publishing peer-reviewed research on genetics, the gut microbiome, and the use of AI to deliver care that is safe, cost-effective, and accessible. Digbi's healthcare cost reduction is documented in multiple peer-reviewed actuarial claims studies. Digbi is accessible to 30 million individuals through more than 300 employers and health plans.
SOURCE Digbi Health
- Obesity Society
- GLP-1
- Gut Microbiome
- Research
- Conference